πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12186349

Compositions and methods for C. difficile treatment

Regents of the University of Minnesota Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187777

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180192

Modulators of THR-Ξ² and methods of use thereof

Aligos Therapeutics, Inc. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12181555

3-dimensional representations of post-contrast enhanced brain lesions

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180503

Methods and compositions for RNA-directed target DNA modification and for RNA-directed mod

The Regents of the University of California Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180484

Chimeric antigen receptors targeting B-cell maturation antigen

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180471

Antisense oligonucleotides for the treatment of Stargardt disease

ProQR Therapeutics II B.V. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180479

Compounds and methods for modulating ATXN1

Ionis Pharmaceuticals, Inc. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180504

Methods and compositions for RNA-directed target DNA modification and for RNA-directed mod

The Regents of the University of California Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180251

Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for tre

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180463

Lactobacillus reuteri

PrecisionBiotics Group Limited Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12179037

Radiotherapies and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178981

Drug administration method

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180084

Cerium (III) carbonate formulations

The Regents of the University of California Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180211

Compounds, compositions and methods

DENALI THERAPEUTICS INC. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180258

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180509

Methods for reprograming non-pluripotent cells into pluripotent stem cells

BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180300

Targeting moiety-drug grafted immune cell compositions and methods of use

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180225

N/O-linked degrons and degronimers for protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178875

Lymphatic system-directing lipid prodrugs

Seaport Therapeutics, Inc. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178887

NIR-conjugated tumor-specific antibodies and uses thereof

The Regents of the University of California Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178921

Method of lyophilizing lipid nanoparticles

ARCTURUS THERAPEUTICS, INC. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178907

Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178868

Immunogenic compositions and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted